Werewolf Therapeutics (NASDAQ:HOWL) Stock Rating Reaffirmed by JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research report report published on Wednesday morning, Benzinga reports. The brokerage currently has a $12.00 price objective on the stock.

A number of other equities research analysts also recently issued reports on the stock. HC Wainwright reiterated a buy rating and set a $15.00 price target on shares of Werewolf Therapeutics in a research report on Wednesday. Wedbush reaffirmed an outperform rating and set a $9.00 price objective on shares of Werewolf Therapeutics in a report on Monday, June 3rd.

Werewolf Therapeutics Stock Down 2.8 %

Werewolf Therapeutics stock opened at $2.44 on Wednesday. The stock’s 50 day moving average price is $4.51 and its 200 day moving average price is $5.09. The company has a market cap of $106.03 million, a PE ratio of -2.24 and a beta of 0.62. The company has a debt-to-equity ratio of 0.24, a current ratio of 6.71 and a quick ratio of 6.71. Werewolf Therapeutics has a 1-year low of $1.57 and a 1-year high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Friday, May 3rd. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). Werewolf Therapeutics had a negative return on equity of 36.15% and a negative net margin of 256.33%. The company had revenue of $0.74 million for the quarter, compared to analyst estimates of $5.00 million. On average, sell-side analysts predict that Werewolf Therapeutics will post -1.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of HOWL. Janus Henderson Group PLC acquired a new stake in Werewolf Therapeutics during the 1st quarter valued at $10,922,000. PFM Health Sciences LP lifted its position in shares of Werewolf Therapeutics by 35.6% in the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after acquiring an additional 909,895 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Werewolf Therapeutics by 26.8% during the first quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock valued at $7,176,000 after acquiring an additional 233,909 shares during the last quarter. Acadian Asset Management LLC increased its position in Werewolf Therapeutics by 119.8% during the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock worth $1,119,000 after purchasing an additional 94,212 shares in the last quarter. Finally, Denali Advisors LLC acquired a new position in Werewolf Therapeutics in the 1st quarter valued at about $172,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.